Xilio TherapeuticsXLO
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 26 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, up 3 from Q1 2026. 11 opened new positions and 6 sold out. The largest holders were Bain Capital Life Sciences Investors, LLC ($6.4M), Orbimed Advisors LLC ($5.7M) and Frazier Life Sciences Management, L.P. ($4.0M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $7.5M |
| Exits | 6 | $1.4M |
All 13F filers, Q1 2026 → Q2 2026: 1,016,549 shares bought and 176,827 shares sold, net +839,722 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 26 holders
| Bain Capital Life Sciences Investors, LLC | 0.38% | No change | 664,021 | $6.4M |
| Orbimed Advisors LLC | 0.11% | New | 592,300 | $5.7M |
| Frazier Life Sciences Management, L.P. | 0.09% | No change | 422,505 | $4.0M |
| Stonepine Capital Management, LLC | 1.65% | Add +252.2% | 225,994 | $2.2M |
| Vanguard Capital Management LLC | 0.00% | Add +44.4% | 178,517 | $1.7M |
| Sio Capital Management, LLC | 0.25% | No change | 152,464 | $1.5M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | New | 111,541 | $1.1M |
| Merck & Co., Inc. | 0.19% | No change | 105,982 | $1.0M |
| Renaissance Technologies | 0.00% | Add +29.4% | 64,153 | $615K |
| Morgan Stanley | 0.00% | Reduce -0.9% | 56,954 | $546K |
| Geode Capital Management, LLC | 0.00% | Add +5.0% | 39,055 | $374K |
| Citadel Advisors | 0.00% | New | 25,950 | $249K |
| Vanguard Fiduciary Trust Co. | 0.00% | Reduce -20.6% | 22,594 | $216K |
| Bridgeway Capital Management, LLC | 0.00% | New | 17,544 | $168K |
| Two Sigma Investments, LP | 0.00% | New | 14,544 | $139K |
| Velan Capital Investment Management LP | 0.08% | No change | 14,285 | $137K |
| Gsa Capital Partners LLP | 0.01% | Reduce -19.8% | 13,590 | $130K |
| State Street Corp. | 0.00% | No change | 13,311 | $128K |
| Prelude Capital Management, LLC | 0.01% | New | 11,600 | $111K |
| BlackRock, Inc. | 0.00% | New | 8,757 | $84K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 714 | $7K |
| Security National Bank of Sioux City Iowa | 0.00% | New | 321 | $3K |
| Barclays PLC | 0.00% | New | 115 | $1K |
| Key Financial Inc | 0.00% | No change | 59 | $565 |
| Jones Financial Companies LLLP | 0.00% | New | 29 | $262 |
| UBS Group AG | 0.00% | Reduce -99.7% | 14 | $134 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.